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Congenital pulmonary lymphangiectasis (CPL) is a rare developmental disorder that has been associated
with primary fetal pleural effusions. A 22 year old, Gravida-1 Caucasian woman presented at 26 gesta-
tional weeks with bilateral pleural effusions and hydrops fetalis. Fetal ultrasound revealed rapidly
expanding pleural effusions and hydrops fetalis. A throacoamniotic shunt was placed in the left pleural
space at 27 gestational weeks. The patient eventually developed severe preeclampsia and non-reassuring
fetal heart tones necessitating immediate cesarean delivery at 32 gestational weeks. Persistent bilateral
pleural effusions were noted after delivery and chest tubes were immediately placed. Despite maximal
ventilatory support, continued bowel rest and an octreotide drip, both chest tubes continued to drain a
signiﬁcant amount of chylous ﬂuid. The neonate eventually developed multi-organ failure and expired on
day of 19. Autopsy ﬁndings revealed diffuse CPL. CPL causes markedly distended pulmonary lymphatics
that result in accumulation of ﬂuid within the fetal pleural spaces. We report a case of CPL associated
fetal pleural effusions managed antenatally by throacoamniotic shunting.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license. Pleural effusions represent an abnormal buildup of ﬂuid be-
tween the layers of tissue that line the lungs and chest cavity.
During fetal life pleural effusions occur infrequently with a reported
incidence of between 1/10,000 and 1/15,000 pregnancies [1]. Pri-
mary fetal pleural effusions (FPEs) most often result from lymphatic
accumulation in the lungs brought about by anomalies in the
thoracic duct, pulmonary tissue, or pleura [2e4]. Secondary FPEs,
on the other hand, are most commonly associated with generalized
ﬂuid retention seen in non-immune hydrops that can occur as a
result of a variety of etiologies such as isoimmunization, fetal ar-
rhythmias, congenital infections, structural heart disease, alpha
thalassemia, aneuploidy, sacrococcygeal teratomas and twin to
twin transfusion syndrome [5e11]. Congenital pulmonary lym-
phangiectasis (CPL) is an extremely rare developmental disorder
characterized by markedly distended pulmonary lymphatics and
has been reported to result in primary FPEs [12].
Although small pleural effusions may remain stable or even
resolve spontaneously, larger ones may lead to fetal hydrops, pul-
monary hypoplasia, esophageal compression with resultant poly-
hydramnios, preterm birth and even stillbirth. Furthermore, FPEs
may prevent expansion of the lung parenchyma postnatally, thus,þ1 816 404 5152.
.
NC-ND license. impeding oxygenation of the neonate following delivery. Ante-
partum pleural decompression has emerged as a potential treat-
ment modality for rapidly enlarging pleural effusions, pleural
effusions resulting in a mediastinal shift or pleural effusions asso-
ciated with hydrops fetalis. Indeed, fetal thoracentesis has been
shown to improve perinatal survival [13e15]. Unfortunately, since
pleural ﬂuid often reaccumulates so rapidly, multiple pleural aspi-
rations are required, thus, cumulatively increasing the risks of
procedure associated morbidity like intrauterine infection, preterm
rupture of membranes, and fetal injury [16]. Alternatively, thor-
acoamniotic shunting can provide continuous pleural decompres-
sion of the fetal pleural space, thus, avoiding the need for multiple
invasive procedures. We report a case of CPL that resulted in
bilateral pleural effusions and hydrops fetalis managed antenatally
by throacoamniotic shunting.
1. Case presentation
A 22 year old, Gravida-1 Caucasian woman was referred to our
perinatal diagnostic center at 26 completed gestational weeks for a
screening fetal ultrasound. The fetus was found to have bilateral
pleural effusions (Fig. 1), scalp edema, and polyhydramnios.
The patient denied any prior medical history and had a negative
workup for hydrops fetalis, including an otherwise normal targeted
Fig. 1. Axial ultrasound view of the fetal chest. Note the presence of bilateral pleural
effusions.
Fig. 3. Axial ultrasound view of the fetal chest one day after placement of the thor-
acoamniotic shunt. The blue arrow represents the thoracoamniotic shunt decom-
pressing the left pleural space. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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maternal antibody screen, complete blood count, KleihauereBetke
staining and maternal TORCH titers. An amniocentesis was per-
formed and revealed a normal female karyotype. Follow-up so-
nography at 27 completed gestational weeks demonstrated
worsening pleural effusions with signiﬁcantly retracted pulmonary
architecture noted bilaterally. Following administration of steroids
for fetal lung maturity, a double pigtail thoracoamniotic catheter
(Harrison shunt, Cook Medical, Inc., Spencer, IN, USA) was placed in
the left pleural space under ultrasound guidance. Due to fetal
positioning, the right pleural space was inaccessible and, thus, was
not shunted. Postoperative ultrasonography performed the next
day revealed a nearly decompressed left pleural space with the
shunt in proper position (Figs. 2 and 3). Serial ultrasounds per-
formed weekly demonstrated a non-expanding right pleural effu-
sion with no evidence of mediastinal deviation and improved signs
of hydrops fetalis. Given that the stable appearance of the right
pleural effusion, right sided pleural drainage was not attempted. At
32 completed weeks the patient developed severe preeclampsiaFig. 2. Sagittal ultrasound view of the fetal chest one day after placement of the
thoracoamniotic shunt demonstrating a reduction in the left pleural effusion (blue
arrow). (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)and non-reassuring fetal heart tones necessitating immediate ce-
sarean delivery. The 1 min, 5 min, and 10 min Apgar scores were 4,
5, and 6 respectively and the birthweight was 2440 g. The arterial
cord pH was 7.309 and the base deﬁcit was 0.4. The neonate
appeared dusky at birth with hypotonia and poor respiratory effort.
Neonatal resuscitation was initiated with bag-masked ventilation,
chest compressions and epinephrine. The infant was intubated and
started on ventilatory support. A chest radiograph was immediately
obtained and revealed bilateral pleural effusions. Bilateral chest
tubes were placed and the thoracoamniotic shunt was removed.
Molecular testing for Noonan’s syndrome was negative for the
PTPN11 gene. Despite continued bowel rest, total parenteral
nutrition and an octreotide drip, both chest tubes continued to
drain over 200 ml/kg of chylous, straw-colored ﬂuid. Repeat chest
radiographs demonstrated hyperinﬂated lungs with persistent
bilateral pleural effusions. The neonate eventually developedmulti-
organ failure and expired on day 19. Autopsy ﬁndings revealed
diffuse CPL.
2. Discussion
First described by Virchow in 1856, congenital pulmonary
lymphangiectasis (CPL) is a rare lymphatic vessel malformation
characterized by abnormally dilated and thin-walled pulmonary
subpleural, interlobar, perivascular, and peribronchial lymphatic
channels. During fetal life lymphatic vessels within the lung nor-
mally begin to diminish in size starting at approximately 20 weeks
of gestation. For unknown reasons, in primary pulmonary lym-
phangiectasia this regression process does not take place and the
persistence of large lymphatic vessels occurs with resultant
development of severe lymphedema. In secondary pulmonary
lymphangiectasia, dilated lymphatic vessels most commonly
develop in conjunction with a variety of congenital heart defects,
such as total anomalous pulmonary venous return, stenosis of the
pulmonary and mitral valves, hypoplastic left heart, cor triatriatum,
atresia of the pulmonary veins and atrioventricular canal defects
[12]. It is hypothesized that cardiac lesions somehow interfere with
the normal regression of the lymphatic tissue elements during the
mid-second trimester [17]. More widespread abnormalities of
lymphatic drainage have also been reported in cases of pulmonary
lymphangiectasia involving dilation of lymphatic vessels in bones,
viscera, and soft tissues.
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isolated cases or small case series have been reported. Autopsy
studies suggest, however, that approximately 0.5e1% of perinatal
deaths may be attributed to CPL [17]. Most cases of CPL are sporadic
and although familial occurrences have been described, no under-
lying genetic etiology has yet been identiﬁed [18e20]. Two familial
conditions inwhich CPLmay occur are Hennekam syndrome, which
presents as congenital lymphedema with facial anomalies, intesti-
nal lymphangiectasia, as well as varying degrees of mental retar-
dation, and Njolstad syndrome, which is characterized by
congenital pulmonary lymphangiectasia along with facial and
lower limb lymphedema. CPL has also been associated with 46,XY/
46,XX mosaicism, ichthyosis congenita, Noonan’s syndrome, Tur-
ner’s syndrome, Fryns syndrome, and Down’s syndrome [21]. The
mortality rate for CPL is variable, ranging from 50% to 98%. Gener-
ally, the prognosis of CPL depends on the severity of symptoms
observed in the immediate postnatal period. CPL associated with
systemic lymphangiectasia seems to have a slightly better prog-
nosis than isolated CPL. The combination of CPL with hydrops
fetalis, bilateral chylothorax or the immediate onset of severe res-
piratory distress at birth has the worst prognosis.
Postnatally, newborns with CPL present with severe respiratory
distress, tachypnea, and cyanosis and mechanical ventilation is
nearly always required. Prompt recognition of respiratory failure,
surfactant administration, pleural decompression, and replacement
of ﬂuid and protein losses is paramount during the neonatal period.
Nutritional support initially consists of total parenteral nutrition
with eventual introduction of a low-fat, high-protein diet, medium-
chain triglycerides, and fat-soluble vitamin supplementation when
pleural drainage ceases. A low-fat intake is thought to aid in
lymphatic decompression by the reduction of lymph ﬂow from
intestinal lymphatics to pulmonary lymphatics. Frequently during
the ﬁrst month of life respiratory relapses and exacerbations occur.
Infants with CPL may have signiﬁcant growth failure and experi-
ence recurring lower respiratory infections during early childhood.
Older children can present with recurrent cough and frequent
wheezing, increased respiratory effort and even congestive heart
failure.
Antenatally, CPL is most commonly associated with chylous
pleural effusions; however, chylopericardium, chylous ascites,
hydrops fetalis, or generalized lymphedema may also be seen. The
antepartum diagnosis of fetal pleural effusions was ﬁrst described
in 1977 [1,22]. Ultrasound is the primary modality for the fetal
diagnosis of pleural effusions and appear as hypoechoic densities
surrounding the lungs that generally conform to the normal con-
tour of the chest [4]. The sonographic appearance of bilateral
pleural effusions often appear as “bat wings” and may be seen both
in the axial and sagittal planes. Primary pleural effusions occur
as a result of intrinsic vascular defects while secondary pleural
effusions may be caused by a variety of etiologies that extrinsically
alter circulatory dynamics and cause hydrops fetalis, such as
bronchopulmonary sequestrations, congenital diaphragmatic her-
nias, structural cardiac defects, cardiac arrhythmias, aneuploidy,
congenital infections, red blood cell alloimmunization and glycogen
storage diseases. Yinon et al. stated that pleural effusions that are
proportionately larger than ﬂuid collections in other parts of the
body are more consistent with primary as opposed to secondary
effusions [16]. Furthermore, pleural ﬂuid with an elevated
lymphocyte count greater than 80% is more characteristic of pri-
mary pleural effusions. The maternal workup for fetal pleural
effusions includes a complete blood count, KleihauereBetke
staining, blood group and antibody screening, hemoglobin elec-
trophoresis as well as toxoplasmosis, cytomegalovirus and parvo-
virus serologies, while the fetal workup includes a detailed
anatomical ultrasound, middle cerebral artery peak systolic velocitymeasurements, fetal echocardiography, karyotype and cytomega-
lovirus, toxoplasmosis, and parvovirus amniotic culture and PCR.
Although the prognosis of secondary pleural effusions is largely
dependent upon treatment of the underlying disorder, spontaneous
resolution of primary pleural effusions has been reported to occur.
Aubard et al. described 204 cases of primary fetal hydrothorax, 22%
of which spontaneously regressed [23]. Effusions that most
commonly resolved occurred when the diagnosis wasmade early in
the second trimester, if the effusion was small and unilateral and
there was an absence of hydrops fetalis. Larger effusions, however,
tend to result in worsening hydrops fetalis from cardiac tamponade
and impaired venous and lymphatic return, increased symptoms of
preterm labor from esophageal compression with resultant poly-
hydramnios and pulmonary hypoplasia due to chronic external
pressure. In cases where enlargement of the pleural effusion results
in mediastinal deviation or signiﬁcant lung retraction, fetal inter-
vention to decompress the ﬂuid collection, either via thoracentesis
or thoracoamniotic shunting has been shown to improve perinatal
survival [14,24]. Recently, Nygaard et al described seven fetuses
with primary pleural effusions who were treated by intrapleural
injection of OK-432, which resulted in complete resolution with no
perinatal mortality [25]. Further studies, however, are needed to
clarify the role of this therapy.
Fetal thoracentesis, an invasive procedure to remove ﬂuid from
the pleural space using a 20 or 22 gage hollow needle, was ﬁrst
described by Peters et al., in 1982 [15]. It has been performed
immediately prior to delivery to facilitate neonatal resuscitation
and to remove excess pleural ﬂuid remote from delivery [13,14].
Indeed, there have been reports of thoracentesis performed for fetal
pleural effusions with complete resolution [13e15]. Unfortunately,
others have reported rapid pleural ﬂuid reaccumulation within
24e48 h of fetal thoracentesis procedures, requiring multiple
decompressive procedures and resulting in increased risks of in-
trauterine infection, preterm rupture of membranes and fetal death
[1,26e28]. Aubard et al. reported 29 cases where fetal thoracentesis
was performed between 17 and 37 weeks. Pleural ﬂuid rapidly
reaccumulated in 76% of fetuses, 13 of which died [23]. Longaker
et al. stated that thoracentesis cannot decompress the fetal chest
enough to allow for pulmonary expansion and prevention of pul-
monary hypoplasia [1].
Thoracoamniotic shunting for fetal pleural effusions was ﬁrst
reported by Booth, Blott, and Rodeck et al. during the late 1980s
[29e31]. Since then, pleural effusions have become one of the
most common indications for in utero shunting. In a review of 47
cases of hydropic fetuses, Picone et al. demonstrated a survival rate
of 66% when thoracoamniotic shunting was performed [32]. Pet-
terson et al. reported on 69 cases of thoracoamniotic shunting and
found a survival rate of 46.3% in hydropic fetuses and 100% in
non-hydropic fetuses [24]. Rustico et al. recently described their
experience of 53 fetuses who underwent thoracoamniotic shunt-
ing, 43 of which were hydropic [33]. Overall survival was 58% for
hydropic fetuses and 90% in non-hydropic fetuses. Finally, in a
large series of 88 patients where thoracoamniotic shunting was
performed, Yinon et al. demonstrated a 52.5% survival in hydropic
fetuses and 72.4% in non-hydropic fetuses [16]. When secondary
causes of FPEs are excluded, the survival rates for fetuses
that undergo thoracoamniotic shunting are markedly increased
[27,28,34]. Although there are no randomized trials comparing
thoracentesis to thoracoamniotic shunting, data analyzed retro-
spectively suggests that for hydropic fetuses with pleural effusions,
thoracoamniotic shunting is associated with higher survival rates
compared to serial fetal thoracentesis [23,24,33]. Complications
of thoracoamniotic shunting include shunt obstruction and cath-
eter migration into the amniotic ﬂuid, fetal pleural space or even
into the maternal peritoneal cavity [31]. Shunt reversal, where
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transient maternal ascites following thoracoamniotic shunt
placement have also been reported [31,35]. Less common fetal
complications of thoracoamniotic shunting include fetal scarring
and limb constriction [36e39]. Procedure-related fetal death is
rare, although may occur from hemorrhage from intercostal artery
laceration or torsion of the umbilical cord [1,11]. Maternal com-
plications of thoracoamniotic shunting include chorioamnionitis,
preterm premature rupture of membranes (PPROM) and preterm
labor.
Management of fetal pleural effusions depend upon the etiol-
ogy, gestational age, rate of progression or regression, and presence
of hydrops. In order to exclude secondary causes of pleural effu-
sions, fetal echocardiography should be performed. In cases of
small, unilateral effusions without hydrops or mediastinal shift, it is
reasonable to proceed without any intervention since spontaneous
regression may occur. It is important, however, that serial ultra-
sounds be performed at least weekly since pleural effusions may
enlarge quickly. Between 24 and 32 gestational weeks, pleural
decompression should be undertaken if mediastinal shifting,
hydrops fetalis or rapid enlargement of the pleural effusion is noted
[24,32,33,40,41]. Thoracentesis can be attempted initially and the
ﬂuid sent for cell count, culture, and karyotype in order to help
further elucidate the etiology of the pleural effusion. An additional
attempt at fetal thoracentesis may be made if the pleural effusion
reaccumulates. Following two thoracentesis procedures, however,
thoracoamniotic shunting should be considered. In fetuses with
bilateral pleural effusions, both pleural spaces should ideally be
decompressed to avoid possible mediastinal shifting that may
occur following unilateral decompression, preferably in a single
operation in order to minimize uterine punctures. Yinon et al.
described a technique of rotating the fetus with the blunt end of the
trocar to gain access to the contralateral side [16]. Prior to 24
gestational weeks, termination of pregnancy may be performed,
especially if the pleural effusion is associated with severe cardiac
anomalies. After 32 gestational weeks, some authors elect to pro-
ceed with delivery for worsening pleural effusions in favor of
postnatal pleural decompression. On the other hand, given the poor
survival of preterm neonates born with hydrops fetalis or signiﬁ-
cant pleural effusions, in utero pleural decompression has been
advocated over premature delivery in any fetus less than 36
gestational weeks [1]. Cesarean section is generally reserved for
obstetrical indication. The thoracoamniotic shunts should be
clamped during delivery in order to avoid development of a
pneumothorax. It’s imperative that intrapartum management be
carried out in appropriately staffed centers capable of performing
appropriate neonatal resuscitation.
3. Conclusion
Large fetal pleural effusions are a source of signiﬁcant perinatal
morbidity. CPL is an extremely rare condition that can result in
signiﬁcant accumulation of pleural ﬂuidwithin the pleural space. To
our knowledge our case represents only the second reported
occurrence of fetal pleural effusions caused by CPL managed with
thoracoamniotic shunting [12]. The recognition of the differential
diagnosis for fetal pleural effusions to include CPL and the under-
standing of various modalities for prenatal surgical intervention is
paramount for practitioners involved in maternal, fetal, and
neonatal medicine.
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